|MBC BioLabs company, Enable Biosciences featured on KTVU for their hassle-free HIV test Full Press Release|
|Enable Biosciences and Stanford researchers develop a hassle-free HIV test that works better, sooner|
|Enable Biosciences, Stanford, and JDRF announce $700K Research Partnership to Develop Improved Screening and Early Diagnosis Tests for Type 1 Diabetes|
Enable Biosciences, a UC Berkeley and Stanford-StartX diagnostics company at MBC BioLabs, and Stanford's Division of Pediatric Endocrinology and Diabetes announce a two-year initiative to support the development of a revolutionary new technology for earlier, easier and more accurate screening tests for type 1 diabetes in children. The $700,000 initiative is funded by a competitive award conferred by JDRF to Stanford as a part of its Prevention research portfolio. "Enable's Antibody Detection by Agglutination PCR technology has the potential to solve many of the core problems that face T1D diagnostics. We are pleased to partner with visionary institutions such as JDRF and Stanford to develop predictive and preventative technologies for children and families affected by T1D." said Peter Robinson, CSO, Enable Biosciences.
The JDRF award will fund efforts to validate the ADAP-powered diabetes test with new samples collected from Stanford hospital, including development and optimization of a saliva-based test for type 1 diabetes. Studies will then compare performance across blood, serum and saliva and develop key standards to optimize collection and storage of samples for general pediatric population screening. "JDRF is excited about the potential of the Enable technology to detect autoantibodies in a small amount of saliva or blood," said Jessica Dunne, JDRF Director, Research. "Prevention is a vital part of JDRF's mission to cure, prevent and treat type 1 diabetes, and an assay like this could remove obstacles and serve as a critical step toward being able to screen all kids for risk of T1D."
Reminder to apply for the 2018 AbbVie Golden Tickets!
AbbVie 2018 Golden Ticket Applications are due this Friday, March 2, 2018. To apply, please email your non-confidential company presentation to GoldenTicket@abbvie.com. Winners will receive one lab bench and core access for one scientist for one year.
Please include the following in your slides:
- What is the scientific insight and approach driving your company?
- If successful, how would your therapeutic approach provide significant patient benefit beyond currently available treatment or other R&D stage programs?
- How will a Golden Ticket impact your company's aims?
- When would you like to start using the space?
|pH Pharma's vision is to discover and develop distinctive and innovative healthcare technologies and therapies. Our therapeutic candidates in clinical development target glaucoma and metabolic syndromes. We are also focused on a pre-clinical program to discover novel oncology therapeutics. pH Pharma was founded in 2015 and is headquartered in Seoul, South Korea with a main Silicon Valley office in Menlo Park, California.|
|Celebration: March 8, 2:00 - 3:00 PM International Women's Day 2018 To celebrate International Women's Day on March 8th, JLABS and MBC BioLabs will be hosting a celebration in our 1st floor conference room! Please come by for cookies and drinks provided by JLABS.|
|Office Hours: March 20, 1:00 - 3:00 PM Amit Raj Dua Global Marketing Strategy Leader, BioProcess Global Electric Healthcare Life Sciences Amit is GE Life Sciences Global Market Strategy Leader in the Bioprocess space and hopes to learn about challenges facing start-ups as they scale, this could be anything from gaps in technology to cost to the political climate! Please contact Linda Eng to schedule an office hour.|
|Amit Dua is the Global Marketing Strategy Leader for GE Healthcare Life Sciences Bioprocess business. Amit's primary focus is to align Bioprocess market insights with technology trends to drive value added initiatives for the biopharmaceutical industry. Amit has been in the Life Sciences industry for 11 years and has held multiple commercial roles in sales, marketing and product management. He also participates in several industry groups such as BioProcess Systems Alliance (BPSA) and International Society of Pharmaceutical Engineers (ISPE) and serves on the Advisory Board for Biopharma Asia and BPI East/West. Amit holds a BS in Bioengineering from Stonybrook University and MBA from Columbia Business School.|
|Lunch and Learn: March 21, 11:00 - 1:00 PM MabSelect PrismA Pierre Tremblay, PhD Chromotography Resin Specialist Global Electric Healthcare Life Sciences RSVP Pierre will introduce the next generation in Protein A chromatography, MabSelect PrismA. This resin demonstrates improved binding capacity in addition to enhanced alkaline stability. In conjunction to an improved high flow agarose base matrix, it provides the attributes for future mAb processing. Pierre Tremblay has been with GE Healthcare for 15 years but started in protein purification as a graduate student. He supported and then lead the BioProcess courses in the GE portfolio, delivering custom courses at industry and academic sites.|